Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2020-04-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
第五届董事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding the approval of the company's 2020 first quarter report. It states that the full quarterly report is available on official disclosure websites and newspapers, indicating this document itself is not the full report but an announcement of the board meeting decision to approve the report. The document length is short (679 characters), and it references the full quarterly report being published elsewhere. Therefore, this is not the Interim/Quarterly Report (IR) itself but an announcement related to it. According to the rules, such announcements are best classified as Regulatory Filings (RNS) since it does not contain substantive financial data but announces the approval and publication of the report.
2020-04-28 Chinese
2020年第一季度报告提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (393 characters) indicating that the full 2020 first quarter report has been published on an official disclosure website. It explicitly states that the full report is available elsewhere and this document serves as a notice to investors to review it. There is no substantive financial data or analysis within this text itself. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA), not the actual Interim/Quarterly Report (IR).
2020-04-28 Chinese
关于预计2020年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected related party transactions for the fiscal year 2020 by 康芝药业股份有限公司. It details the nature, amounts, and approval process of these transactions, including board meeting resolutions and independent director opinions. The content focuses on disclosure of anticipated related party dealings rather than financial results, management changes, or legal proceedings. It is not a full financial report, audit report, or earnings release. The document is a regulatory announcement about related party transactions, which fits best under the category of Regulatory Filings (RNS) as it does not match any more specific category such as Capital/Financing Update or Board/Management Information. The document length is about 5,054 characters, which is sufficient for a substantive announcement rather than a brief report publication notice.
2020-04-27 Chinese
关于聘请公司2020年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the appointment of the company's audit firm for the 2020 fiscal year. It details the selection process, qualifications, and background of the audit firm, as well as the approval by the board and supervisory committee. There are no financial statements or audit results presented, only the announcement of the appointment of the auditor. The document length is 4613 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement related to the auditor appointment, not the audit report itself. FY 2020
2020-04-27 Chinese
关于举行2019年度业绩网上说明会的通知
AGM Information Classification · 95% confidence The document is a notice about holding an online performance explanation meeting for the 2019 annual results of 康芝药业股份有限公司. It references that the 2019 annual report has already been published on April 28, 2020, and invites investors to participate in the online meeting scheduled for May 12, 2020. The document is short (669 characters) and serves as an announcement for an event related to the annual report, not the report itself. Therefore, it fits the category of AGM Information (AGM-R) as it is about an annual general meeting presentation or explanation session.
2020-04-27 Chinese
2019年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2019 年年度报告摘要" which translates to "2019 Annual Report Summary". It contains detailed company information, business overview, financial data for multiple years including revenue, net profit, and other financial indicators, as well as operational and investment discussions. The document includes comprehensive financial and operational data typical of an annual report. It is not a brief announcement or a certification, but a substantive report covering the full fiscal year 2019. Therefore, it fits the definition of an Annual Report (10-K). FY 2019
2020-04-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.